How to Get Retatrutide Legally in 2026: Clinical Trials Only, and What to Use Until Approval

Written by Olha Orlyk. Updated October 25, 2026.

As of October 2026, the only legal way to get retatrutide is to enroll in a clinical trial. The drug is not approved anywhere, cannot be prescribed, and is not stocked by any pharmacy; Eli Lilly plans to file for FDA approval in the first quarter of 2027, which puts a decision in late 2027 or 2028. Everything sold online as "retatrutide," "reta" or "GLP-3 RT" is unapproved, unverified and, under U.S. law, illegal to sell for human use.

This guide explains how retatrutide trials work and how to find one, what you get and what you risk by joining, why the online vials are not a shortcut, what the Phase 3 results so far say, the realistic timeline to a prescription, and what to use in the meantime.

Retatrutide (LY3437943) is an investigational drug. In the United States, a drug can be prescribed only after FDA approves a marketing application, and Lilly has not yet filed one. Until then, the Food, Drug, and Cosmetic Act allows the drug to be given to people only inside an FDA-regulated clinical trial, under an investigational new drug application, with informed consent and safety monitoring. There is no compassionate-use or early-access program for retatrutide for obesity, and no compounding pathway, because compounding is permitted only for approved drugs or listed bulk substances, which retatrutide is not. Our what is retatrutide guide covers the drug itself.

Lilly's Phase 3 program, called TRIUMPH, has enrolled thousands of adults with obesity, with and without diabetes, heart disease, sleep apnea and knee osteoarthritis. Several TRIUMPH studies finished in 2026; others, including the long-term outcomes trial and newer studies, are still enrolling or will open. Here is how to find and join one.

Placebo is the sticking point for most people. Some trials offer an open-label extension where everyone receives the drug after the blinded phase, and some newer studies compare retatrutide with an active drug rather than placebo; the listing will say which.

These are the largest weight losses recorded in any obesity drug trial. The cost is tolerability: vomiting affected about a quarter of people on 12 mg in TRIUMPH-1, abnormal skin sensations (dysesthesia) about one in eight, and 11% to 18% stopped because of side effects at the top dose. Lilly is testing slower dose increases to manage this. We track every readout in approval watch and compare the numbers with Zepbound in retatrutide vs tirzepatide.

Dozens of websites sell powder labeled "retatrutide," "RT3" or "GLP-3 RT" with a "research use only" disclaimer. Three things to know. First, the disclaimer does not make the sale legal: FDA's warning letters state that marketing a product with claims about appetite and fat loss shows it is intended for human use, which makes it an unapproved new drug. Second, nobody verifies what is in the vial; independent tests of research peptides have found wrong doses, contamination and the wrong molecule entirely. Third, people have been harmed: Public Citizen counted 14 hospitalizations linked to unapproved retatrutide in FDA's adverse event database by June 2026, and FDA has issued at least 14 warning letters to sellers. The trial drug comes with slow dose escalation and monitoring for a reason. Our guide to what GLP-3 RT actually is goes through the seller claims one by one.

For most people the practical answer is tirzepatide now, with a switch considered once retatrutide is approved. See retatrutide vs Ozempic, Wegovy and Zepbound for the full comparison.

If you are weighing a clinical trial against waiting for approval, it helps to know what the trial drug actually does over time. See how fast retatrutide works for the week-by-week weight-loss timeline from the phase 2 and TRIUMPH-1 trials, including why the first three months are deliberately slow.

You cannot buy, be prescribed or legally obtain retatrutide outside a clinical trial in October 2026, and that will stay true until FDA acts on Lilly's planned 2027 filing. Trials are free, supervised and give you the genuine drug, at the price of placebo odds and a demanding schedule. Online vials carry the drug's trial-level risks with none of its safeguards, and FDA has made clear the sales are illegal. If you cannot or do not want to join a trial, tirzepatide is the closest approved option, and switching later will be straightforward. Trial-reported side effects are listed on our side effects page; the dose schedules used in the studies are in retatrutide dosage in clinical trials.

This article is for information only and is not medical advice. Retatrutide is investigational; do not buy or inject unapproved products.